Foghorn director granted 28,000 stock options

Foghorn Therapeutics director Michael Mendelsohn received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share.

Rhea-AI Filing Summary

Foghorn Therapeutics director Michael Mendelsohn received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options were awarded as compensation and give him the right to buy shares at that price in the future.

The options vest in full on the first anniversary of the grant date, as long as he continues to serve on the board of directors. After this grant, he holds 28,000 stock options directly, with an expiration date in 2036, providing long-term equity-based incentives tied to the company’s share performance.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider Mendelsohn Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Underlying shares: 28,000 shares +3 more

6 metrics

Options granted 28,000 options Stock options covering common stock granted to director

Exercise price $4.08 per share Option strike price for underlying common stock

Underlying shares 28,000 shares Common stock underlying the granted options

Expiration date 2036-06-23 Options expire in 2036 if not exercised

Vesting schedule 1-year cliff vesting Vests in full on first anniversary of grant date

Post-grant holdings 28,000 options Total options held directly after this grant

Key Terms

Stock Options (Right to buy), grant/award acquisition, exercise price, vests in full, +1 more

5 terms

Stock Options (Right to buy) financial

"security_title: Stock Options (Right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 4.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"The option vests in full on the first anniversary"

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Michael Mendelsohn acquire in Foghorn Therapeutics (FHTX)?

Michael Mendelsohn received a grant of stock options for 28,000 shares of Foghorn Therapeutics common stock. These options allow him to purchase shares at a fixed $4.08 exercise price if they vest and he chooses to exercise.

What is the exercise price of the new Foghorn Therapeutics (FHTX) options?

The granted stock options have an exercise price of $4.08 per share. This means Mendelsohn can buy Foghorn Therapeutics common stock at $4.08 if he exercises the options after they vest and before expiration.

When do Michael Mendelsohn’s Foghorn Therapeutics (FHTX) options vest?

The stock options vest in full on the first anniversary of the grant date. Vesting is conditional on Mendelsohn’s continued service on Foghorn Therapeutics’ board of directors through that one-year period, aligning compensation with board tenure.

How many Foghorn Therapeutics (FHTX) options does Mendelsohn hold after this grant?

Following this transaction, Mendelsohn holds 28,000 stock options directly. All of these options relate to Foghorn Therapeutics common stock and were acquired in the same grant, establishing his current derivative equity position from this filing.

When do the newly granted Foghorn Therapeutics (FHTX) options expire?

The granted stock options expire in 2036, giving a long-term window to exercise. This extended expiration allows Mendelsohn to potentially benefit from Foghorn Therapeutics’ share performance over many years if the options vest and become valuable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mendelsohn Michael

(Last) (First) (Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		(1)	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Michael Mendelsohn	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)